MADRIGAL PHARMACEUTICALS, INC. business relationships
Companies named in MADRIGAL PHARMACEUTICALS, INC.’s 10-K filed 2026-02-19, and public companies whose annual reports name MADRIGAL PHARMACEUTICALS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.5 / 10
- AI naming
- <1 / 100 Top 67% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Layers: GLP-1 & obesity
Named in MADRIGAL PHARMACEUTICALS, INC.’s annual report 3
“In December 2025, we entered into an exclusive global license agreement with Pfizer (the "Pfizer License Agreement") to develop, manufacture and commercialize ervogastat, a Phase 2 oral DGAT-2 inhibitor, and two additional early-stage MASH assets.” SEC filing
“Our composition-of-matter patent licensed from Roche relating to resmetirom is scheduled to expire in the United States in 2026.” SEC filing
“We have also entered into a supply agreement (the "Corden Supply Agreement") with Corden Pharma GmbH ("Corden"), a German-based manufacturer, for the primary commercial supply of Rezdiffra tablets in Europe and to serve as a secondary commercial supplier for the U.S. market.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.